Image

Interventions for Promoting Kidney Transplant Empowerment

Interventions for Promoting Kidney Transplant Empowerment

Recruiting
18-75 years
All
Phase N/A

Powered by AI

Overview

This is a cluster randomized controlled clinical trial evaluating the effect of community health workers (CHWs) and provider education on kidney transplant (KTx) waitlisting compared to usual care (waitlist control). CKD/HD providers will be randomized to intervention or control, and all patients with the same providers will be in the same randomization group. CHWs will address unmet social needs and patient symptoms through evaluations and linkage to clinical and community services. Intervention providers will receive education, which will include training on working with CHWs, reducing bias in clinical decision-making, and increasing affirming/reducing stigmatizing language in electronic health records (EHRs).

Eligibility

Inclusion Criteria:

  • Patient inclusion:
    • Provision of signed and dated informed consent from the patient.
    • Stated willingness to comply with all study procedures and availability for the duration of the study.
    • Age 18 - 75 years
    • eGFR≤20 mL/min/1.73m2 or on maintenance in-center HD.
    • Receive kidney care at Mount Sinai, Einstein, Bellevue Hospital, NYU, or hemodialysis at a participating HD Center.
    • Community dwelling (i.e., not in a nursing home, currently incarcerated).
    • Speak English and/or Spanish.
  • Provider Inclusion:
    • Provision of signed and dated informed consent from the nephrologist.
    • Stated willingness to comply with all study procedures and availability for the duration of the study.

Exclusion Criteria:

  • Patient Exclusion:
    • Absolute contraindications to KTx:
      • Self-reported or documented diagnosis of dementia, or inability to understand the study and complete informed consent. When the participant's understanding is unclear, the CRC will use a modified MOCA screener to determine eligibility.
      • Active malignancy (excluding local non-melanoma skin cancer, renal cell carcinoma <5 cm, early thyroid cancer, and prostate cancer GS≤6).
      • Pregnancy (can be re-evaluated post-delivery).
      • Active infection. Patients excluded due to active infection will be evaluated at 30 days or after completing full treatment (whichever is later) to determine eligibility. Examples of active infection include:
        • Positive cultures or radiographic evidence of infection
        • Infected intravascular devices, such as tunneled catheters and pacemakers
        • Active histoplasmosis, cryptococcosis, tuberculosis (TB), and nontuberculous mycobacteria
    • Previously evaluated by KTx and not listed for specific medical reasons.
    • Patients previously evaluated and not listed will be carefully reviewed by site PI for eligibility
    • Already listed for KTx.
    • Patients on other types of dialysis other than in-center hemodialysis.
    • Self-identify as already engaged with a CHW at participating sites to address unmet social needs.
    • Planning to move out of the greater NY area in the next 1 year.
  • Provider Exclusion:
    • Planning to leave their respective institutions in the next 1 year

Study details
    Kidney Transplant Waitlisting

NCT06655857

Icahn School of Medicine at Mount Sinai

15 October 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.